2. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10:515–31. Doi: 10.1517/14728222.10.4.515.

3. Wagner E., Siafis S., Fernando P., et al. Efficacy and safety of clozapine in psychotic disorders – a systematic quantitative meta-review. Transl Psychiatry. 2021;11(1):487. Doi: 10.1038/ s41398-021-01613-2.

4. Данилов Д.С. Классификация антипсихотических средств и их значение для выбора терапии шизофрении (к 60-летию появления нейролептиков). Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(10):91–100.

5. Weston-Green K. Antipsychotic drug development: from historical evidence to fresh perspectives. Front Psychiatry. 2022;13:903156. Doi: 10.3389/ fpsyt.2022.903156.

6. Vassilopoulou E., Efthymiou D., Papatriantafyl- lou E., et al. Long term metabolic and inflammatory effects of second-generation antipsychotics: a study in mentally disordered offenders. J Pers Med. 2021;11:1189. Doi: 10.3390/jpm11111189.

7. Naber D., Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuro-Psychopharmacol Biol Psychiatry. 2004;28:1213–19. Doi: 10.1016/j. pnpbp.2004.06.020.

8. Pahwa M., Sleem A., Elsayed O.H., et al. New antipsychotic medications in the last decade. Curr Psych Rep. 2021;23:87. Doi: 10.1007/s11920- 021-01298-w.

9. Wong D.F., Raoufinia A., Bricmont P., et al. An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. Eur J Clin Pharmacol. 2021;77:717–25. Doi: 10.1007/s00228-020- 03021-9.

10. Mailman R., Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16:488–501. Doi: 10.2174/138161210790361461.

11. Tariot P.N., Ballard C., Devanand D.P., et al. Pimavanserin and dementia-related psychosis. Lancet. Neurol. 2022;21:114–15. Doi: 10.1016/ S1474-4422(21)00466-X.

12. Lobo M.C, Whitehurst T.S., Kaar S.J., Howes O.D. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324–61. Doi: 10.1016/j. neubiorev.2021.11.032.

13. Greenwood J., Acharya R.B., Marcellus V., Rey J.A. Lumateperone: a novel antipsychotic for schizophrenia. Ann Pharmacother. 2021;55:98– 104. Doi: 10.1177/1060028020936597.

14. Paik J. Olanzapine/samidorphan: first approval. Drugs. 2021;81:1431–36. Doi: 10.1007/s40265- 021-01568-0.

15. Rehan S.T., Siddiqui A.H., Khan Z., et al. Samidorphan/ olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. An Med Surg (Lond). 2022;79:104115. Doi: 10.1016/j. amsu.2022.104115.

16. Weiden P.J., Breier A., Kavanagh S., et al. Antipsychotic efficacy of KarXT (xanomeline-trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psych. 2022;11(83):21m14316. Doi: 10.4088/JCP.21m14316.

17. Brannan S.K., Sawchak S., Miller A.C., et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Eng J Med. 2021;384:717–26. Doi: 10.1056/ NEJMoa2017015.

18. Opler L.A., Medalia A., Opler M.G., et al. Pharmacotherapy of cognitive deficits in schizophrenia. CNS Spectrums. 2014;19:142–56. Doi: 10.1017/S1092852913000771.

19. Moсолов С.Н., Смулевич А.Б., Незнанов Н.Г. и др. Применение агонистов mGlu2/3 – новый подход к терапии шизофрении: результаты рандомизированного двойного слепого исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;110(7):16–23.

20. Мирошниченко И.И., Вальдман Е.А., Кузьмин И.И. Новое предназначение старых лекарств. Разработка и регистрация лекарственных средств. 2022. В печати.

21. Romero-Miguel D., Lamanna-Rama N., Casquero- Veiga M., et al. Minocycline in neurodegenerative and psychiatric diseases: An update. Eur J Neurol. 2021;28:1056–81. Doi: 10.1111/ene.14642.

22. Сakici N., van Beveren N. J. M., Judge-Hundal G., et al. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta- analysis. Psychol Med. 2019;49:2307–19. Doi: 10.1017/S0033291719001995.